The Prevent nCoV Project

A Danish vaccine candidate against COVID-19 is developed by a team of researchers at the Department of Immunology and Microbiology at the University of Copenhagen in collaboration with the companies AdaptVac, ExpreS2ion Biotechnologies and Bavarian Nordic. 

In January 2021, the researchers from the Department of Immunology and Microbiology at the Faculty of Health and Medical Sciences at UCPH published the results of the effect of the vaccine in Nature Communications. They showed that one dosage of ABNCoV2 is very efficient. If the results of the clinical test are just as promising as the researchers expect them to be, the hope is, that this vaccine against Covid-19 will be ready by the end of 2021 or beginning of 2022.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Funding

The research is funded by the Carlsberg Foundation, the Independent Research Fund Denmark, Horizon 2020 and Gudbjørg and Ejnar Honoré’s Foundation. 

Overall budget€ 3 399 387,50

Project: Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine

Grant agreement ID: 101003608 

Periode: April 1 2020 - September 30 2021.